New scan could predict chemotherapy success in stomach cancer
NCT ID NCT04560036
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a special type of PET/MRI scan, using a tracer called FAZA, can measure low oxygen levels (hypoxia) in tumors of patients with metastasized gastro-oesophageal cancer. The goal is to see if this scan can predict how well patients will respond to standard chemotherapy. Forty adults with this cancer will get two scans—one before and one after chemotherapy—but the results won't change their treatment plan.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FAZA (a radioactive tracer used in PET/MRI scans)
What this could lead to
If successful, this could lead to a way to predict which patients will respond to chemotherapy, helping doctors choose more effective treatments.
What could go wrong
This is a small, early pilot study with only 40 participants. The scan results will not change treatment, so it is purely exploratory and may not lead to a usable test.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC GASTROESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Univeristy Health Network
RECRUITINGToronto, Ontario, M5G 2N2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact